<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">bekhterev</journal-id><journal-title-group><journal-title xml:lang="ru">Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева</journal-title><trans-title-group xml:lang="en"><trans-title>V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7053</issn><issn pub-type="epub">2713-055X</issn><publisher><publisher-name>V. M. BEKHTEREV  NATIONAL  RESEARCH  MEDICAL  CENTER  FOR  PSYCHIATRY  AND  NEUROLOGY                           OF    THE  RUSSIAN  FEDERATION   MINISTRY  OF  HEALTH</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">bekhterev-83</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>В ПОМОЩЬ ПРАКТИКУЮЩЕМУ ВРАЧУ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>GUIDELINES FOR THE PRACTITIONER</subject></subj-group></article-categories><title-group><article-title>Назначения лекарств: проблемы и пути решения</article-title><trans-title-group xml:lang="en"><trans-title>Prescription of drugs: problems and ways of solving</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лутова</surname><given-names>Наталия Борисовна</given-names></name><name name-style="western" xml:lang="en"><surname>Lutova</surname><given-names>N. B.</given-names></name></name-alternatives><email xlink:type="simple">lutova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский научно-исследовательский психоневрологический институт им. В.М. Бехтерева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>St.-Peresburg V.M. Bekhterev Psychoneurological Research Institute</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>19</day><month>07</month><year>2018</year></pub-date><volume>0</volume><issue>2</issue><fpage>87</fpage><lpage>90</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лутова Н.Б., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Лутова Н.Б.</copyright-holder><copyright-holder xml:lang="en">Lutova N.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.bekhterevreview.com/jour/article/view/83">https://www.bekhterevreview.com/jour/article/view/83</self-uri><abstract><p>В статье рассматривается место и значение инъекционных пролонгированных форм антиписхотических препаратов при лечении больных шизофренией, указываются их преимущества и недостатки, а также проблемы, связанные с их назначением. Описывается алгоритм вовлечения больных в процесс лечения, конкретные действия врача при назначении препарата.</p></abstract><trans-abstract xml:lang="en"><p>In the article considers the place and value of the long-acting injectable antipsychotics in schizophrenia, summarized the advantages and disadvantages as well as problems related to their prescribing. Described the algorithm for patient’s engagement in the process of treatment and the specific doctor’s actions when prescribing the drug.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>шизофрения</kwd><kwd>медикаментозный комплайенс</kwd><kwd>пролонгированные формы антипсихотиков второго поколения</kwd><kwd>терапевтический альянс</kwd><kwd>вовлечение пациента</kwd><kwd>schizophrenia</kwd><kwd>medication compliance</kwd><kwd>long-acting injectable antipsychotics</kwd><kwd>therapeutic alliance</kwd><kwd>patient’s engagement</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Лутова Н.Б. Пролонгированные формы антипсихотиков в повседневной клинической практике (результаты опроса больных) // Журнал неврологии и психиатрии им. С.С. Корсакова. 2014. - № 10. - С. 65-68.</mixed-citation><mixed-citation xml:lang="en">Лутова Н.Б. Пролонгированные формы антипсихотиков в повседневной клинической практике (результаты опроса больных) // Журнал неврологии и психиатрии им. С.С. Корсакова. 2014. - № 10. - С. 65-68.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Морозова М.А. Палиперидона пальмитат - возможности терапии обострений у больных шизофренией пролонгированными атипичными антипсихотиками // Журнал неврологии и психиатрии. - 2012. - № 2. - С. 85 -88.</mixed-citation><mixed-citation xml:lang="en">Морозова М.А. Палиперидона пальмитат - возможности терапии обострений у больных шизофренией пролонгированными атипичными антипсихотиками // Журнал неврологии и психиатрии. - 2012. - № 2. - С. 85 -88.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мосолов С.Н., Калинин В.В. Еремин А.В. Сравнительная эффективность и переносимость нового поколения антипсихотических средств при лечении обострений шизофрении (метаанализ оригинальных исследований оланзапина, рисперидона, кветиапина, клозапина и галоперидола) // Новые достижения в терапии психических заболеваний/ Под ред. С.Н. Мосолова. - М. - 2002. - С. 82-94.</mixed-citation><mixed-citation xml:lang="en">Мосолов С.Н., Калинин В.В. Еремин А.В. Сравнительная эффективность и переносимость нового поколения антипсихотических средств при лечении обострений шизофрении (метаанализ оригинальных исследований оланзапина, рисперидона, кветиапина, клозапина и галоперидола) // Новые достижения в терапии психических заболеваний/ Под ред. С.Н. Мосолова. - М. - 2002. - С. 82-94.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Незнанов Н.Г., Иванов М.В. Роль пролонгированных лекарственных форм в улучшении клинической картины и социальной адаптации пациентов с диагнозом шизофрении// Психиатрия и психофармакотерапия. - 2012 - Т. 14. - № 3. - С. 2-7.</mixed-citation><mixed-citation xml:lang="en">Незнанов Н.Г., Иванов М.В. Роль пролонгированных лекарственных форм в улучшении клинической картины и социальной адаптации пациентов с диагнозом шизофрении// Психиатрия и психофармакотерапия. - 2012 - Т. 14. - № 3. - С. 2-7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Шрайнер А., Аадамсу К., Альматура А.С., и др. Рандомизированное двухлетнее со слепой оценкой исследование палиперидона пальмитата в сравнении с монотерапией выбранным исследователями пероральным антипсихотиком у больных шизофренией (PROSIPAL) расширенный реферат // Современная терапия психических расстройств. - 2016. - № 2. - С. 9-16.</mixed-citation><mixed-citation xml:lang="en">Шрайнер А., Аадамсу К., Альматура А.С., и др. Рандомизированное двухлетнее со слепой оценкой исследование палиперидона пальмитата в сравнении с монотерапией выбранным исследователями пероральным антипсихотиком у больных шизофренией (PROSIPAL) расширенный реферат // Современная терапия психических расстройств. - 2016. - № 2. - С. 9-16.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Янушко М.Г., Либин Л.Я. Практические рекомендации по применению палиперидона пальмитата в лечении шизофрении. - М.: МЕДпресс-информ. - 2015. - 32с.</mixed-citation><mixed-citation xml:lang="en">Янушко М.Г., Либин Л.Я. Практические рекомендации по применению палиперидона пальмитата в лечении шизофрении. - М.: МЕДпресс-информ. - 2015. - 32с.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Altamura A., Sassella F., et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice // Drugs. - 2003. - Vol. 63. - P. 493-512.</mixed-citation><mixed-citation xml:lang="en">Altamura A., Sassella F., et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice // Drugs. - 2003. - Vol. 63. - P. 493-512.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Argo T.R., Crimson M.L., Miller A.L., et al. The Texas Medication Algorthm Project antipsychotic algorithm for schizophrenia. The Texas Department of State Health Services. - 2007.</mixed-citation><mixed-citation xml:lang="en">Argo T.R., Crimson M.L., Miller A.L., et al. The Texas Medication Algorthm Project antipsychotic algorithm for schizophrenia. The Texas Department of State Health Services. - 2007.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bai Y., Chen T., et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-weeks randomized, single-blind study // Pharmacopsychiatry. - 2006. - Vol. 39(4). - P. 135-141.</mixed-citation><mixed-citation xml:lang="en">Bai Y., Chen T., et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-weeks randomized, single-blind study // Pharmacopsychiatry. - 2006. - Vol. 39(4). - P. 135-141.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Barrio P., Batalla A., Castellve P., et al. Effectiveness of long-acting injectable risperidine versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. - Int Clinical Psychopharmacology. - 2013. - Vol. 28. - P. 164-170.</mixed-citation><mixed-citation xml:lang="en">Barrio P., Batalla A., Castellve P., et al. Effectiveness of long-acting injectable risperidine versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study. - Int Clinical Psychopharmacology. - 2013. - Vol. 28. - P. 164-170.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Berwaerts J., Liu Y., Gopal S., Nuamah I., et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia. A randomized clinical trial. - JAMA Psychiatry. - 2015. - Vol. 72. - P. 830-839.</mixed-citation><mixed-citation xml:lang="en">Berwaerts J., Liu Y., Gopal S., Nuamah I., et al. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia. A randomized clinical trial. - JAMA Psychiatry. - 2015. - Vol. 72. - P. 830-839.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Boca R., FlaWalburn J., Gray R., et al. Systematic review of patient and nurse attitudes to depot natipsychotics medication // Br J Psychiatry. - 2001. - Vol. 179. - P. 300-307.</mixed-citation><mixed-citation xml:lang="en">Boca R., FlaWalburn J., Gray R., et al. Systematic review of patient and nurse attitudes to depot natipsychotics medication // Br J Psychiatry. - 2001. - Vol. 179. - P. 300-307.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Care Quality Commission. Mental health services: the 2008 survey of community mental health services. CQC 2009 (http://www.cgc.org.uk/usingcare-services/healthcare/patient-servey/mentalhealthservices.cfm</mixed-citation><mixed-citation xml:lang="en">Care Quality Commission. Mental health services: the 2008 survey of community mental health services. CQC 2009 (http://www.cgc.org.uk/usingcare-services/healthcare/patient-servey/mentalhealthservices.cfm</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Coppola D., Liu Y., Gopal S., Remmerie B., et al. One-year prospective study of the safety, tolerability and pharmacokinetics of the heist available dose of paliperidone palmitate in patients with schizophrenia. - BMS Psychiatry. - 2012. - Vol. 12. - P. 26.</mixed-citation><mixed-citation xml:lang="en">Coppola D., Liu Y., Gopal S., Remmerie B., et al. One-year prospective study of the safety, tolerability and pharmacokinetics of the heist available dose of paliperidone palmitate in patients with schizophrenia. - BMS Psychiatry. - 2012. - Vol. 12. - P. 26.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Emsley R. Il costo reale della non aderenza nella schizophrenia. - Mind Brain. - 2010. - Vol. 1. - P. 17-20.</mixed-citation><mixed-citation xml:lang="en">Emsley R. Il costo reale della non aderenza nella schizophrenia. - Mind Brain. - 2010. - Vol. 1. - P. 17-20.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Falfai P. Wodbrock T., Lieberman J., et al. World Federation Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. - World J Biolog Psychiatry. - 2005. - Vol. 6. - P. 132-191.</mixed-citation><mixed-citation xml:lang="en">Falfai P. Wodbrock T., Lieberman J., et al. World Federation Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. - World J Biolog Psychiatry. - 2005. - Vol. 6. - P. 132-191.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Greenson R.R. The working alliance and the transference neurosis // Psychoanal. Q. - 1965. - Vol. 34. - P. 155-181.</mixed-citation><mixed-citation xml:lang="en">Greenson R.R. The working alliance and the transference neurosis // Psychoanal. Q. - 1965. - Vol. 34. - P. 155-181.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hamann J., Koble J., Cohen R., et al. How do Psychiatrists choose among different antipsychotics? Eur J Clin Psychiatry. - 2005. - Vol. 61. - P. 851-854.</mixed-citation><mixed-citation xml:lang="en">Hamann J., Koble J., Cohen R., et al. How do Psychiatrists choose among different antipsychotics? Eur J Clin Psychiatry. - 2005. - Vol. 61. - P. 851-854.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Heres S., Schmitz F.S., Leucht S., et al. The attitude of patients towards antipsychotic depotreatment. - Int Clin Psychopharmacol. - 2007. - Vol. 22. - P. 275-282.</mixed-citation><mixed-citation xml:lang="en">Heres S., Schmitz F.S., Leucht S., et al. The attitude of patients towards antipsychotic depotreatment. - Int Clin Psychopharmacol. - 2007. - Vol. 22. - P. 275-282.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Heres S., Lambert M., Vauth R., Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. - European Psychiatry. - 2014. - Vol. 29. - P. 1409-1413.</mixed-citation><mixed-citation xml:lang="en">Heres S., Lambert M., Vauth R., Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. - European Psychiatry. - 2014. - Vol. 29. - P. 1409-1413.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Iyer S., Banks N., Roy M.A., et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part 1 -Physicians perspective. - Can J Psychiatry. - 2013. - Vol. 58. - P. 23-29.</mixed-citation><mixed-citation xml:lang="en">Iyer S., Banks N., Roy M.A., et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: Part 1 -Physicians perspective. - Can J Psychiatry. - 2013. - Vol. 58. - P. 23-29.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Jaeger M., Rossler W. Attitudes towards long-acting depot anyipsychotics: A survey patients, relatives and nurses // Psychiarty Res. - 2010. - Vol. 175 (Issue 1-2). - P. 58-62.</mixed-citation><mixed-citation xml:lang="en">Jaeger M., Rossler W. Attitudes towards long-acting depot anyipsychotics: A survey patients, relatives and nurses // Psychiarty Res. - 2010. - Vol. 175 (Issue 1-2). - P. 58-62.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Jeong H.G., Lee M.S. Long-acting injectable antipsychotics in first-episode schizophrenia. - Clinical Psychopharmacological and Neuroscience. - 2013. - Vol. 11. - P. 1-6.</mixed-citation><mixed-citation xml:lang="en">Jeong H.G., Lee M.S. Long-acting injectable antipsychotics in first-episode schizophrenia. - Clinical Psychopharmacological and Neuroscience. - 2013. - Vol. 11. - P. 1-6.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Linden M., Pyrkosch L., Dittmann RW., Czekalla J., Why do physicians switch from one antipsychotic agent to another? The “physician drug stereotype”. - J Clin Psychopharmacology. - 2006. - Vol. 26. - P. 225-231.</mixed-citation><mixed-citation xml:lang="en">Linden M., Pyrkosch L., Dittmann RW., Czekalla J., Why do physicians switch from one antipsychotic agent to another? The “physician drug stereotype”. - J Clin Psychopharmacology. - 2006. - Vol. 26. - P. 225-231.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Luborsky L. Helping alliance in psychotherapy // Successful Psychotherapy / ed. by J. L. Claghorn. - New York, NY: Brunner / Mazel Inc. - 1976. - P. 92-116.</mixed-citation><mixed-citation xml:lang="en">Luborsky L. Helping alliance in psychotherapy // Successful Psychotherapy / ed. by J. L. Claghorn. - New York, NY: Brunner / Mazel Inc. - 1976. - P. 92-116.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Nasrallah H.A, Targum S.D., Tandon R., et al. Defining and measuring clinical effectiveness in the treatment of schizoprenia // Psychiatr Serv. - 2005. - Vol. 56. - P. 273-282.</mixed-citation><mixed-citation xml:lang="en">Nasrallah H.A, Targum S.D., Tandon R., et al. Defining and measuring clinical effectiveness in the treatment of schizoprenia // Psychiatr Serv. - 2005. - Vol. 56. - P. 273-282.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Patel M.X., Haddad R.M., Chaudry I.B., et al. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years // J Psychopharmac. - 2010. - Vol. 24. - P. 1473-1482.</mixed-citation><mixed-citation xml:lang="en">Patel M.X., Haddad R.M., Chaudry I.B., et al. Psychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years // J Psychopharmac. - 2010. - Vol. 24. - P. 1473-1482.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Patel M.X., Nikolaou V., David A.S. Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-89.</mixed-citation><mixed-citation xml:lang="en">Patel M.X., Nikolaou V., David A.S. Psychiatrists’ attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-89.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Potkin S., Bera R., Zubek D., Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics an analysis of in-office discussion regarding LAI for schizophrenia // BMC Psychiatry. - 2013. - Vol. 13. - P. 261.</mixed-citation><mixed-citation xml:lang="en">Potkin S., Bera R., Zubek D., Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics an analysis of in-office discussion regarding LAI for schizophrenia // BMC Psychiatry. - 2013. - Vol. 13. - P. 261.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Schooler N.R. Relapse and rehospitalization: comparing oral and depot antipsychotics // J Clin Psychiatry. - 2003. - Vol. 64. - P. 14-17.</mixed-citation><mixed-citation xml:lang="en">Schooler N.R. Relapse and rehospitalization: comparing oral and depot antipsychotics // J Clin Psychiatry. - 2003. - Vol. 64. - P. 14-17.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Stevens G.L., Dawson G., Zummo J. Clinical benefits and impact of early use of long-acting injectible antipsychotics for schizophrenia. Early Intervention in Psychiatry. - 2015. - №. 1. - P. 1-13.</mixed-citation><mixed-citation xml:lang="en">Stevens G.L., Dawson G., Zummo J. Clinical benefits and impact of early use of long-acting injectible antipsychotics for schizophrenia. Early Intervention in Psychiatry. - 2015. - №. 1. - P. 1-13.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Viala A., Cornic F., Vacheron MN. Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia. - Schizophernia Res and Treatment. - 2012. - P. 1-5.</mixed-citation><mixed-citation xml:lang="en">Viala A., Cornic F., Vacheron MN. Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia. - Schizophernia Res and Treatment. - 2012. - P. 1-5.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Waddell L., Taylor M. Attitudes of patients and mental health staff to antipsychotic long acting injections: systematic review. - Br J Psychiatry. - 2009. - Vol. 195. - P. 43-50.</mixed-citation><mixed-citation xml:lang="en">Waddell L., Taylor M. Attitudes of patients and mental health staff to antipsychotic long acting injections: systematic review. - Br J Psychiatry. - 2009. - Vol. 195. - P. 43-50.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Zetzel E.R. Current concepts of transference / E.R. Zetzel // Int. J. Psychoanal. - 1956. - Vol. 37. - P. 369-376.</mixed-citation><mixed-citation xml:lang="en">Zetzel E.R. Current concepts of transference / E.R. Zetzel // Int. J. Psychoanal. - 1956. - Vol. 37. - P. 369-376.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
